Search company, investor...

Predict your next investment

Janssen Pharmaceuticals company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
janssen.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

2

Partners & Customers

10

About Janssen Pharmaceuticals

Janssen Pharmaceuticals provides medicines for an array of health concerns in several therapeutic areas. It includes attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar disorder, schizophrenia), neurological (Alzheimer's disease, epilepsy, migraine prevention and treatment), pain management, and women's health. The company was founded in 1953 and is based in Raritan, New Jersey.

Headquarters Location

1000 U.S. Highway 202 South

Raritan, New Jersey, 08869,

United States

+1 800 775 5514

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Janssen Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Janssen Pharmaceuticals in 1 Expert Collection, including Medical Devices.

M

Medical Devices

72 items

https://www.amdm.org/members.html

Janssen Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Janssen Pharmaceuticals Rank

Research containing Janssen Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Janssen Pharmaceuticals in 3 CB Insights research briefs, most recently on Sep 19, 2022.

Latest Janssen Pharmaceuticals News

Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Nov 25, 2022

This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection. Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Lonafarnib: Eiger Biopharmaceuticals Eiger's lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection. JNJ-73763989: Janssen Pharmaceuticals Janssen "breakthrough" drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection. Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Hepatitis Delta Virus (HDV) Infection There are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III include, Eiger Biopharmaceuticals. Phases Late-stage products (Phase III)

Janssen Pharmaceuticals Investments

7 Investments

Janssen Pharmaceuticals has made 7 investments. Their latest investment was in Morphic Therapeutic as part of their Corporate Minority on February 2, 2019.

CBI Logo

Janssen Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/21/2019

Corporate Minority

Morphic Therapeutic

Yes

1

1/6/2016

Project Finance

Subscribe to see more

Subscribe to see more

10

12/22/2015

Grant

Subscribe to see more

Subscribe to see more

10

9/28/2015

Project Finance

Subscribe to see more

Subscribe to see more

10

1/13/2015

Partnership

Subscribe to see more

Subscribe to see more

10

Date

2/21/2019

1/6/2016

12/22/2015

9/28/2015

1/13/2015

Round

Corporate Minority

Project Finance

Grant

Project Finance

Partnership

Company

Morphic Therapeutic

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Janssen Pharmaceuticals Portfolio Exits

2 Portfolio Exits

Janssen Pharmaceuticals has 2 portfolio exits. Their latest portfolio exit was Morphic Therapeutic on June 27, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/27/2019

IPO

$99M

Public

2

4/3/2017

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/27/2019

4/3/2017

Exit

IPO

Divestiture

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

2

10

Janssen Pharmaceuticals Acquisitions

4 Acquisitions

Janssen Pharmaceuticals acquired 4 companies. Their latest acquisition was Yumanity Therapeutics - Neurology Assets on July 07, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/7/2022

$99M

Acquired

2

2/2/2022

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/19/2015

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

7/7/2022

2/2/2022

12/2/2020

3/19/2015

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Janssen Pharmaceuticals Partners & Customers

10 Partners and customers

Janssen Pharmaceuticals has 10 strategic partners and customers. Janssen Pharmaceuticals recently partnered with Sonnet BioTherapeutics on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/1/2022

Partner

United States

Sonnet BioTherapeutics Shares Jump 36% After Janssen Collaboration

Shares of Sonnet were up by over a third to $ 2.62 in early trading , building on gains from the day before when the company announced a collaboration with Johnson & Johnson 's Janssen Biotech Inc. .

1

10/31/2022

Partner

United States

Sonnet BioTherapeutics Up 66% in Regular Session on Collaboration With Janssen

Shares of Sonnet BioTherapeutics surged 66 % to $ 1.93 in Monday 's regular session after the company announced a collaboration agreement with Janssen Biotech Inc. .

1

10/27/2022

Partner

China

1

6/14/2022

Licensor

Germany

Subscribe to see more

Subscribe to see more

10

6/9/2022

Licensor

Denmark

Subscribe to see more

Subscribe to see more

10

Date

11/1/2022

10/31/2022

10/27/2022

6/14/2022

6/9/2022

Type

Partner

Partner

Partner

Licensor

Licensor

Business Partner

Country

United States

United States

China

Germany

Denmark

News Snippet

Sonnet BioTherapeutics Shares Jump 36% After Janssen Collaboration

Shares of Sonnet were up by over a third to $ 2.62 in early trading , building on gains from the day before when the company announced a collaboration with Johnson & Johnson 's Janssen Biotech Inc. .

Sonnet BioTherapeutics Up 66% in Regular Session on Collaboration With Janssen

Shares of Sonnet BioTherapeutics surged 66 % to $ 1.93 in Monday 's regular session after the company announced a collaboration agreement with Janssen Biotech Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Janssen Pharmaceuticals Team

43 Team Members

Janssen Pharmaceuticals has 43 team members, including current Chief Executive Officer, Matthew Mulvey.

Name

Work History

Title

Status

Matthew Mulvey

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Matthew Mulvey

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Janssen Pharmaceuticals to Competitors

M
Mundipharma International

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. They are also committed to independent thinking and ground breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting‐edge treatments to meet the most pressing needs of healthcare professionals and patients.

G
Grunenthal Group

The Grunenthal Group is a science-based pharmaceutical company that seeks to bring treatments and technologies to patients worldwide. The company focuses on pain management and related diseases.

E
Eli Lilly and Company

Eli Lilly and Company is a drug firm that focuses on neuroscience, endocrinology, cancer, and immunology. Its key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, and Humulin for diabetes, and Taltz and Olumiant for immunology. The company was founded in 1876 and is based in Indianapolis, Indiana.

GSK Logo
GSK

GSK (GlaxoSmithKline) (NYSE: GSK) develops and markets pharmaceuticals, vaccines, over-the-counter medicines, and health care products. The company was founded in 1830 and is based in Middlesex, U.K.

Roche Holding Logo
Roche Holding

Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops, and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions which are the pharmaceuticals division and the diagnostics division. The company was founded in 1896 and is based in Basel, Switzerland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.